Tactile Systems Tech Bolsa (NASDAQ: TCMD)

Últimas noticias sobre Tactile Systems Tech (NASDAQ:TCMD) Bolsa

Tactile Systems Tech

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Technology Inc

Needham analyst Charles Shi maintains Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) with a Buy and raises the price target from $225 to $270.

News

Price Target

Analyst Ratings

Needham Maintains Buy on Taiwan Semiconductor, Raises Price Target to $270

Accenture Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) announced on Tuesday that <a href="https://www.benzinga.com/pressreleases/25/07/b46188712/accenture-acquires-systema-to-drive-manufacturing-automation-for-semiconductor-clients">it has acquired</a> SYSTEMA GmbH, a Dresden-based software and consulting firm that specializes in automation solutions for the semiconductor and high-tech sectors.
The deal strengthens Accenture&#8217;s digital manufacturing capabilities; the financial terms were not disclosed. Headquartered in Dresden, SYSTEMA brings expertise in bridging legacy systems with modern automation technologies.
The acquisition aligns with Europe&#8217;s efforts to boost domestic semiconductor production, a priority amid growing global demand. SYSTEMA&#8217;s proficiency in connecting legacy systems with modern technologies will enhance Accenture&#8217;s ability to modernize industrial operations across the region.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46166236/palantir-accenture-partner-to-infuse-ai-into-federal-agency-workflows" target="_blank" rel="noreferrer noopener">Palantir, Accenture Partner To Infuse AI Into Federal Agency Workflows</a>
Christina Raab, who leads Accenture&#8217;s operations across Austria, Switzerland, and Germany, emphasized the strategic value of the deal. &#8220;The semiconductor industry underpins much of today&#8217;s technology, and SYSTEMA&#8217;s specialized knowledge enhances our ability to support this complex sector,&#8221; she said.
Sarat Maitin, who heads Accenture&#8217;s digital engineering and manufacturing practice in the region, noted that the acquisition expands Accenture&#8217;s capacity to cover the full manufacturing value chain. &#8220;We aim to be a long-term strategic partner helping European clients remain competitive,&#8221; he said.
SYSTEMA is well-versed in SAP-based manufacturing execution systems and Critical Manufacturing solutions. Beyond semiconductors, the company serves industries such as aerospace, automotive, medical devices, and chemicals.
More than 240 SYSTEMA employees will join Accenture&#8217;s Industry X division, which focuses on digital manufacturing. As of May 31, 2025, Accenture held <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/46024923/accenture-new-bookings-fall-in-q3-but-it-raises-profit-outlook" rel="noreferrer noopener">$9.64 billion</a> in cash and equivalents.
Related ETFs: iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>), Global X Robotics &amp; Artificial Intelligence ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTZ#NASDAQ">BOTZ</a>).
Price Action: ACN shares closed 1.16% higher at $298.89 on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46188671/nvidia-microsoft-on-track-to-achieve-4-trillion-market-cap-says-analyst-dan-ives-tech-bull-market-is-still-early" target="_blank" rel="noreferrer noopener">Nvidia, Microsoft On Track To Achieve $4 Trillion Market Cap, Says Analyst Dan Ives: &#8216;Tech Bull Market Is Still Early&#8217;</a></li>
</ul>
Photo via Shutterstock

Tech

BOTZ

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Accenture Deepens Semiconductor Expertise With Dresden-Based SYSTEMA Buy

SHYF

The Shyft Group Merges With Aebi Schmidt To Form Global Specialty Vehicle Leader; New Aebi Schmidt Group Begins NASDAQ Trading July 1

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) with a Buy and maintains $30 price target.

Reiteration

TYRA

HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target

DCGO

DocGo Awarded $3.4M Multi-Year Contract To Provide Ambulance Services For Albany Stratton VA Medical Center Veterans In Upstate New York

LITM

Snow Lake To Invest AUD$1.4M In GTi Energy's AUD$4.5M Equity Financing To Support Advancement Of Lo Herma ISR Amenable Uranium Project

Federal Reserve

Treasury Secretary Bessent On Fox News, Said On Fed, I Will Go Where I Am Needed But We Have A Lot To Do At Treasury

Compass Point analyst Giuliano Bologna initiates coverage on New Fortress Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) with a Buy rating and announces Price Target of $8.5.

Initiation

Compass Point Initiates Coverage On New Fortress Energy with Buy Rating, Announces Price Target of $8.5

Active Ingredient Manufacturing Transfer to the U.S. Complete&nbsp;
PRINCETON, N.J., July 1, 2025 /PRNewswire/ --&nbsp;Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active ingredient under its partnership agreement with Sterling Pharma Solutions (Sterling). The transfer from Europe to the United States (U.S.) included the optimization and implementation of a commercially viable, scalable production process for this important active ingredient, which is used in the topical drug product formulations <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=193312477&amp;u=https%3A%2F%2Fwww.hybryte.com%2F&amp;a=HyBryte%E2%84%A2">HyBryte&#x2122;</a> and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=1271944488&amp;u=https%3A%2F%2Fwww.soligenix.com%2Fpipeline-programs%2Fsgx302-for-mild-to-moderate-psoriasis%2F&amp;a=SGX302">SGX302</a> being developed for the treatment of cutaneous T-cell lymphoma (CTCL) and psoriasis, respectively. Synthetic hypericin is a potent photosensitizer that is topically applied to skin lesions. Soligenix and Sterling have enabled cGMP (current good manufacturing practice) manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.

SNGX

Soligenix Transfers Manufacturing Process For Synthetic Hypericin Active Ingredient Under Partnership Agreement With Sterling Pharma Solutions

Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that result in blindness. This worldwide, non-exclusive license is pursuant to the agreement between Abeona and Beacon, announced in July 2024, to evaluate the therapeutic potential of AAV204.
AAV204, a novel AAV capsid from the AIM&#x2122; capsid library licensed by Abeona from the University of North Carolina at Chapel Hill, has been shown to achieve high macular and optic nerve transduction levels after para-retinal administration and has also been shown to facilitate transduction of both the inner and outer retina after intravitreal administration in mice and non-human primates.
"Beacon's option exercise further validates AAV204's potential to enable targeted delivery of gene therapies in rare and prevalent ophthalmic diseases," said Dr. Madhav Vasanthavada, Chief Commercial Officer and Head of Business Development at Abeona Therapeutics. "Our non-exclusive agreement with Beacon enables us to fully explore the therapeutic value of AAV204 in additional ophthalmic diseases."
The exercise of this license option concludes Beacon's initial evaluation of the AAV204 capsid for development and commercialization of gene therapies and gives Beacon the right to use AAV204 in connection with up to five gene or ophthalmology disease targets. Under the terms of the agreement, Abeona will receive an undisclosed upfront license payment with additional payments upon the achievement of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating AAV204.

Biotech

General

ABEO

Abeona Therapeutics Announces It Has Exercised Its Option To License Abeona's Patented Aav204 Capsid For Use In Potential Gene Therapies

Financing

Snow Lake To Invest AUD$1.4M In GTi Energy's AUD$4.5M Eqiuty Financing To Support Advancement Of Its Lo Herma ISR Amenable Uranium Project

&nbsp;Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active ingredient under its partnership agreement with Sterling Pharma Solutions (Sterling). The transfer from Europe to the United States (U.S.) included the optimization and implementation of a commercially viable, scalable production process for this important active ingredient, which is used in the topical drug product formulations <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=193312477&amp;u=https%3A%2F%2Fwww.hybryte.com%2F&amp;a=HyBryte%E2%84%A2">HyBryte&#x2122;</a> and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=1271944488&amp;u=https%3A%2F%2Fwww.soligenix.com%2Fpipeline-programs%2Fsgx302-for-mild-to-moderate-psoriasis%2F&amp;a=SGX302">SGX302</a> being developed for the treatment of cutaneous T-cell lymphoma (CTCL) and psoriasis, respectively. Synthetic hypericin is a potent photosensitizer that is topically applied to skin lesions. Soligenix and Sterling have enabled cGMP (current good manufacturing practice) manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.

Soligenix Announces That is Successfully Manufactured Synthetic Hypericin At Sterling Pharma Solutions

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Adaptive's clonoSEQ&#xAE; test for measurable residual disease (MRD) assessment in lymphoid malignancies into OncoEMR&#xAE;, Flatiron's cloud-based Electronic Medical Record (EMR) platform.
Integrating clonoSEQ within OncoEMR simplifies and accelerates access to MRD testing to over 4,500 clinicians across the Flatiron network of 1,000 community-based cancer care locations in the U.S. This integration enables providers to order and review clonoSEQ MRD testing results directly within the EMR, leading to more efficient testing workflows and increasing real-time insights into the patient's disease status.
This integration will be effective as of today, July 1, 2025, to all OncoEMR's MPI users. clonoSEQ will continue to be available to providers outside the Flatiron network through a rapidly expanding number of other EMR integrations and via Adaptive's online diagnostic portal.
 &nbsp;

ADPT

Adaptive Biotechnologies Integrates Adaptive's clonosSEQ Test For MRD Assessment In Lymphoid Malignancies Into OncoEMR, Flatiron's Cloud-Based EMR Platform

CGTX

Cognition Therapeutics Study Of Zervimesine (CT1812) For Early Alzheimer's Disease Surpasses 50% Enrollment Target

AMC Enters Transaction Support Agreement With Creditor Groups; Includes ~$223.3M Of New Money Financing, Immediate Conversion Of $143.0M Of 6.00%/8.00% Senior Secured Exchangeable Notes due 2030 And Resolution Of Litigation With Certain Holders Of 7.5% Senior Secured Notes due 2029

Canaccord Genuity analyst Richard Close initiates coverage on Omada Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) with a Buy rating and announces Price Target of $27.

OMDA

Canaccord Genuity Initiates Coverage On Omada Health with Buy Rating, Announces Price Target of $27

QMCO: -15% &#x7C; <a href="https://www.benzinga.com//node/46181747">Quantum shares are trading lower after the company delayed its FY25 10-K filing due to an ongoing review of its accounting.</a>
&nbsp;
CLRO: 140% &#x7C; <a href="https://www.benzinga.com//node/46182384">ClearOne Declares One-Time Special Stock Dividend On The Co's Issued And Outstanding Shares Of Common Stock And Any Common Stock Equivalents With Dividend Rights To Legacy Stockholders With A 100% Stake In The Proceeds From Any Eventual Sale Of All Or Substantially All Of The Co's Current Assets And Operations In One Or More Transactions</a>
&nbsp;
GPUS: 117% &#x7C; <a href="https://www.benzinga.com//node/46190175">Hyperscale Data's Ault Markets Plans To Launch Decentralized Cryptocurrency Exchange To Be Based In US, With Headquarters In Las Vegas, Nevada</a>

Movers

Trading Ideas

CLRO

GPUS

QMCO

Market-Moving News for July 1st

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering of $100 million of shares of its common stock. Nektar is selling 4,255,320 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $23.50 per share. The gross proceeds to Nektar from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Nektar has granted the underwriters a 30-day option to purchase up to an additional 638,298 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.&nbsp;All of the securities being sold in this offering are being offered by Nektar. The offering is expected to close on July 2, 2025, subject to the satisfaction of customary conditions.
Nektar intends to use the net proceeds from the offering for general corporate purposes, which may include research and development, clinical development and manufacturing costs to support the advancement of its drug candidates, as well as other general corporate purposes.
 &nbsp;

Offerings

NKTR

Nektar Therapeutics Prices Underwritten Public Offering Of $100M Of Shares At $23.50/Shr

Nouveau Monde Graphite Pays Q2 2025 Accrued Interest To Investissement Québec via Share Issuance

UK's CMA Considering Whether Global Payments / Worldpay Merger Will Reduce Competition Within Any Market

Press Releases

Tactile Medical to Present at the Piper Sandler 36th Annual Healthcare Conference

Management

Tactile Medical Appoints Laura King to Board of Directors

Health Care

Tactile Medical Expands Launch of Nimbl™ to Include Patients with Lower Extremity Lymphedema

Tactile Medical to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 18, 2025

Earnings

Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Tactile Medical to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Tactile Medical to Release First Quarter of Fiscal Year 2025 Financial Results on May 5, 2025

Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results

Tactile Medical to Present at Upcoming Investor Conferences in June

New Data Demonstrates Significant Clinical and Quality-of-Life Benefits of Flexitouch® Plus in Treating Lymphedema Among Head and Neck Cancer Survivors

Comments

Tactile Systems Tech

Noticias

Últimas noticias sobre Tactile Systems Tech (NASDAQ:TCMD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL